NetraMark Holdings Inc. (TSX:AIAI)
Canada · Delayed Price · Currency is CAD | Market Cap | 81.53M -25.9% |
| Revenue (ttm) | 165.26K -80.4% |
| Net Income | -5.80M |
| EPS | -0.07 |
| Shares Out | 92.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,982 |
| Average Volume | 30,238 |
| Open | 0.9000 |
| Previous Close | 0.9000 |
| Day's Range | 0.8000 - 0.9200 |
| 52-Week Range | 0.8000 - 1.8000 |
| Beta | 1.48 |
| RSI | 38.48 |
| Earnings Date | May 13, 2026 |
About NetraMark Holdings
NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada. [Read more]
Financial Performance
In fiscal year 2025, NetraMark Holdings's revenue was 432,495, a decrease of -5.18% compared to the previous year's 456,127. Losses were -5.22 million, 56.7% more than in 2024.
Financial StatementsNews
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transform...
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference
TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence so...
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence s...
NetraMark Closes Final Tranche of $3.5 Million Private Placement
TORONTO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
CSE Bulletin: Delist - NetraMark Holdings Inc. (AIAI)
Toronto, Ontario--(Newsfile Corp. - Le 17 février/February 2026) - The common shares of NetraMark Holdings Inc. (the "Issuer") will be delisted from the CSE at market close today, February 17, 2026. T...
Netramark Announces Uplisting to Toronto Stock Exchange
TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company focused on AI-driven clinical trial optimizatio...
NetraMark Strengthens Board Of Directors
TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
NetraMark Closes First Tranche of Private Placement
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
TORONTO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
NetraMark Announces Private Placement Financing
TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
NetraMark Delivers Transformational Quarter Of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award Secured Contract Backlog Expands to C$2.5M, FDA CPIM ...
NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
NetraMark Achieves Major FDA Milestone
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...
NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...
NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformi...
Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...
NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tr...
NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming...
Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transformin...
NetraMark to Attend Canaccord Genuity's 45th Annual Growth Conference
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transformin...
NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transformin...
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transformin...
NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...